Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRS051
MIFTS: 57

Breast Disease

Categories: Reproductive diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Breast Disease

About this section

MalaCards integrated aliases for Breast Disease:

Name: Breast Disease 11 14 16 75
Breast Diseases 53 41 43 71

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:3463
ICD9CM 34 610-612.99
MeSH 43 D001941
NCIt 49 C26709
SNOMED-CT 68 79604008
UMLS 71 C0006145
Sources

Summaries for Breast Disease

About this section

MedlinePlus: 41 Most women experience breast changes at some time. Your age, hormone levels, and medicines you take may cause lumps, bumps, and discharges (fluids that are not breast milk). If you have a breast lump, pain, discharge or skin irritation, see your health care provider. Minor and serious breast problems have similar symptoms. Although many women fear cancer, most breast problems are not cancer. Some common breast changes are: Fibrocystic breast changes - lumpiness, thickening and swelling, often just before a woman's period Cysts - fluid-filled lumps Fibroadenomas - solid, round, rubbery lumps that move easily when pushed, occurring most in younger women Intraductal papillomas - growths similar to warts near the nipple Blocked milk ducts Milk production when a woman is not breastfeeding NIH: National Cancer Institute

MalaCards based summary: Breast Disease, also known as breast diseases, is related to microglandular adenosis and breast cancer, and has symptoms including pruritus, exanthema and pelvic pain. An important gene associated with Breast Disease is PRLR (Prolactin Receptor), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Acetylcholine and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and skin, and related phenotypes are homeostasis/metabolism and neoplasm

Disease Ontology: 11 A thoracic disease that is located in the breast.

Wikipedia: 75 Breast diseases make up a number of conditions. The most common symptoms are a breast mass, breast pain,... more...
Sources

Related Diseases for Breast Disease

About this section

Diseases related to Breast Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 519)
# Related Disease Score Top Affiliating Genes
1 microglandular adenosis 32.8 PGR ESR1 ERBB2 CTSD
2 breast cancer 32.6 VEGFA TP53 TNF TFF1 RHOC PRLR
3 hypertrophy of breast 32.3 TP53 PGR ESR1 ERBB2
4 breast abscess 32.1 PGR ERBB2
5 cystic fibrosis 31.8 VEGFA TP53 TNF IGFBP3 IGF1 ESR1
6 breast fibroadenoma 31.8 TP53 TFF1 PGR ESR1 ERBB2 CTSD
7 ductal carcinoma in situ 31.7 VEGFA TP53 PGR ESR2 ESR1 ERBB2
8 papilloma 31.4 VEGFA TP53 ERBB2 EGF BCL2
9 lobular neoplasia 31.2 TP53 PGR ESR1 ERBB2
10 gynecomastia 31.2 PGR KLK3 ESR2 ESR1 ERBB2
11 breast ductal carcinoma 31.2 TP53 TFF1 PGR ESR2 ESR1 ERBB2
12 breast fibroadenosis 31.0 PGR ESR1 ERBB2
13 intraductal papilloma 31.0 PGR ESR1 ERBB2
14 female breast cancer 30.9 TP53 PGR KLK3 ESR2 ESR1 ERBB2
15 mammary paget's disease 30.9 PGR ESR1 ERBB2
16 endometriosis 30.9 VEGFA TP53 PGR MIR199A1 ESR2 ESR1
17 prostate cancer 30.7 VEGFA TP53 TNF RHOC PRLR PGR
18 gastric cancer 30.7 VEGFA TP53 TNF TFF1 MIR199A1 IGF1
19 adenocarcinoma 30.7 VEGFA TP53 KLK3 ERBB2 EGF BCL2
20 tubular adenocarcinoma 30.6 PGR ESR1 ERBB2 CTSD
21 insulin-like growth factor i 30.6 VEGFA IGFBP3 IGF1 ESR1 EGF
22 bilateral breast cancer 30.6 TP53 PGR ESR1 ERBB2
23 cowden syndrome 30.6 TP53 PGR ESR1 ERBB2
24 hereditary breast ovarian cancer syndrome 30.5 TP53 PGR ESR1 ERBB2
25 ovarian cancer 30.5 VEGFA TP53 TNF TFF1 PGR MIR199A1
26 lymphangioma 30.5 VEGFA TP53 TNF MIR199A1 EGF BCL2
27 meningioma, familial 30.5 VEGFA TP53 PRLR PGR IGF1 ESR1
28 ovarian disease 30.4 VEGFA TP53 TNF PGR MIR199A1 IGF1
29 breast carcinoma in situ 30.4 VEGFA TP53 PGR ESR2 ESR1 ERBB2
30 leiomyoma 30.4 TP53 PGR ESR2 ESR1 EGF COMT
31 breast lobular carcinoma 30.4 TP53 PGR ESR1 ERBB2 EGF
32 body mass index quantitative trait locus 11 30.4 VEGFA TP53 TNF MIR199A1 IGFBP3 IGF1
33 breast malignant phyllodes tumor 30.4 TP53 PGR ESR1 ERBB2
34 apocrine adenocarcinoma 30.4 TP53 PGR ESR1 ERBB2
35 inflammatory breast carcinoma 30.4 RHOC PGR ESR1 ERBB2
36 sporadic breast cancer 30.4 TP53 PGR ESR1 ERBB2
37 vascular disease 30.4 VEGFA TP53 TNF MIR199A1 IGF1 ESR1
38 type 2 diabetes mellitus 30.4 VEGFA TP53 TNF MIR199A1 IGFBP3 IGF1
39 uterine corpus cancer 30.4 TP53 PGR ESR1 ERBB2
40 li-fraumeni syndrome 30.4 TP53 ESR1 ERBB2 BCL2
41 cystitis 30.4 VEGFA TP53 TNF EGF
42 estrogen excess 30.4 PGR ESR2 ESR1
43 galactorrhea 30.3 PRLR IGF1
44 type 1 diabetes mellitus 30.3 VEGFA TNF IGFBP3 IGF1 COMT
45 fasciitis 30.3 TP53 TNF ESR1
46 fallopian tube carcinoma 30.3 VEGFA TP53 ERBB2
47 leiomyoma, uterine 30.3 PGR ESR2 ESR1
48 mastitis 11.3
49 diabetic mastopathy 11.0
50 multiple fibroadenomas of the breast 11.0

Graphical network of the top 20 diseases related to Breast Disease:



Diseases related to Breast Disease
Sources

Symptoms & Phenotypes for Breast Disease

About this section

UMLS symptoms related to Breast Disease:


pruritus; exanthema; pelvic pain; mastodynia; breast engorgement; nipple discharge; signs and symptoms in breast; other signs and symptoms in breast; breast pain female

MGI Mouse Phenotypes related to Breast Disease:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 BCL2 COMT CTSD CYP1A1 CYP1B1 ERBB2
2 neoplasm MP:0002006 10.4 BCL2 CYP1B1 ERBB2 ESR1 ESR2 IGF1
3 endocrine/exocrine gland MP:0005379 10.35 BCL2 COMT CTSD CYP1A1 EGF ERBB2
4 nervous system MP:0003631 10.34 BCL2 COMT CTSD ERBB2 ESR1 ESR2
5 growth/size/body region MP:0005378 10.34 BCL2 CTSD CYP1A1 EGF ERBB2 ESR1
6 muscle MP:0005369 10.29 BCL2 ERBB2 ESR1 ESR2 IGF1 IGFBP3
7 normal MP:0002873 10.27 CYP1A1 EGF ERBB2 ESR1 ESR2 IGF1
8 limbs/digits/tail MP:0005371 10.24 ERBB2 ESR1 ESR2 IGF1 IGFBP3 PGR
9 cellular MP:0005384 10.22 BCL2 CTSD ERBB2 ESR1 ESR2 IGF1
10 no phenotypic analysis MP:0003012 10.17 CYP1A1 ESR1 ESR2 MIR199A1 PGR TNF
11 cardiovascular system MP:0005385 10.15 BCL2 COMT ERBB2 ESR1 ESR2 IGF1
12 adipose tissue MP:0005375 10.13 BCL2 ESR1 ESR2 IGF1 IGFBP3 PRLR
13 digestive/alimentary MP:0005381 10.13 BCL2 CTSD EGF ERBB2 ESR1 ESR2
14 immune system MP:0005387 10.13 BCL2 COMT CTSD CYP1A1 EGF ESR1
15 embryo MP:0005380 10.11 BCL2 COMT ERBB2 ESR1 PGR PRLR
16 reproductive system MP:0005389 10.03 BCL2 COMT EGF ERBB2 ESR1 ESR2
17 skeleton MP:0005390 9.85 ERBB2 ESR1 ESR2 IGF1 IGFBP3 PGR
18 hematopoietic system MP:0005397 9.73 BCL2 COMT CTSD CYP1A1 ERBB2 ESR1
19 integument MP:0010771 9.44 BCL2 CTSD EGF ERBB2 ESR1 ESR2
Sources

Drugs & Therapeutics for Breast Disease

About this section

Drugs for Breast Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Tocopherol Approved, Investigational Phase 4 1406-66-2
3
Tamoxifen Approved Phase 4 10540-29-1, 54965-24-1 2733526
4
Trastuzumab Approved, Investigational Phase 4 180288-69-1
5
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
6
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
7
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
8
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
9
Tocotrienol Investigational Phase 4 6829-55-6 9929901
10 Neurotransmitter Agents Phase 4
11
abobotulinumtoxinA Phase 4
12 Botulinum Toxins, Type A Phase 4
13 Botulinum Toxins Phase 4
14 Cholinergic Agents Phase 4
15 Retinol palmitate Phase 4
16 Omega 3 Fatty Acid Phase 4
17 Vitamins Phase 4
18 Tocotrienols Phase 4
19 Tocopherols Phase 4
20 Antimetabolites Phase 4
21 Antineoplastic Agents, Hormonal Phase 4
22 Estrogens Phase 4
23 Estrogen Receptor Antagonists Phase 4
24 Estrogen Antagonists Phase 4
25 Hormone Antagonists Phase 4
26 Estrogen Receptor Modulators Phase 4
27 Selective Estrogen Receptor Modulators Phase 4
28 Evening Primrose Phase 4
29 Hypolipidemic Agents Phase 4
30 Lipid Regulating Agents Phase 4
31 Dermatologic Agents Phase 4
32 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate Phase 4
33 Chelating Agents Phase 4
34 Antihypertensive Agents Phase 4
35
Angiotensinogen Phase 4 16133225
36 Angiotensin Receptor Antagonists Phase 4
37 Angiotensin II Type 1 Receptor Blockers Phase 4
38 Giapreza Phase 4
39 Sacubitril and valsartan sodium hydrate drug combination Phase 4
40
Evening primrose oil Investigational, Nutraceutical Phase 4 308064-97-3
41
Epirubicin Approved Phase 2, Phase 3 56420-45-2 41867
42
Goserelin Approved Phase 2, Phase 3 65807-02-5 5311128 47725
43
Ibuprofen Approved Phase 3 15687-27-1 3672
44
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
45
Ketamine Approved, Vet_approved Phase 3 6740-88-1, 1867-66-9 3821
46
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
47
Remifentanil Approved Phase 3 132875-61-7 60815
48
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
49
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
50
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial Unknown status NCT01427400 Phase 4 Botulinum Toxin-A;Saline
2 A Multicenter, Randomized, Open, Parallel Controlled Clinical Study on the Efficacy and Safety of the Treatment of Cyclomastopathy With Xiaoru Sanjie Capsule Unknown status NCT02929420 Phase 4 Xiaoru Sanjie capsules;Xiao Yao pills
3 Omega-3 Fatty Acids Plus Vitamin E Cosupplementation Versus Vitamin E in Fibrocystic Breast Patient Unknown status NCT04694027 Phase 4 Omega 3 fatty acid;VitaE
4 Single-shot Pectoral Plane (PECs) Blocks Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECs Block and Local Anaesthetic Infusion After Non-ambulatory Breast Cancer Surgery: A Prospective, Randomised, Double-blind Trial Completed NCT03024697 Phase 4
5 A Single Blinded Randomized Controlled Trial of the Comparative Effects of Tamoxifen and Evening Primrose Oil in Premenopausal Non-high Risk Patients With Benign Breast Disease With Respect to the Estrogen Receptor Status. Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
6 Contrast Enhanced Breast MRI: Comparison of Two Macrocyclic Gadolinium-Based Contrast Agents: Gadoterate Meglumine (Dotarem) and Gadobutrol (Gadavist). A Prospective Study. Recruiting NCT03730051 Phase 4 Gadoterate meglumine;Gadobutrol
7 Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent Not yet recruiting NCT05465031 Phase 4 Sacubitril-valsartan
8 A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer Unknown status NCT01917279 Phase 3 Docetaxel plus Capecitabine;Intermittent Capecitabine;Metronomic Capecitabine
9 Prospective Randomized Controlled Study on the Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer Unknown status NCT03373708 Phase 2, Phase 3 Epirubicin;Cyclophosphamide;Docetaxel;Goserelin acetate;Tamoxifen;Letrozole
10 Randomized Controlled Trials of Diet and Lifestyle Intervention to Promote Chinese Postpartum Women's Health Unknown status NCT01039051 Phase 2, Phase 3
11 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGenâ„¢ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease Unknown status NCT00237523 Phase 3 IoGen (molecular iodine)
12 A Multicenter, Randomized, Open-label, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. Versus Charcotrace Inj. in Patients With Nonpalpable Breast Lesions Completed NCT04606329 Phase 3 LuminoMark inj.(Conc. for fluorescence);Charcotrace Inj.
13 Monitored Anesthesia Care Using Remifentanil and Ketofol Results in a Superior Quality of Recovery Compared With Total Intravenous Anesthesia in Ambulatory Breast Augmentation Completed NCT03764267 Phase 3 Remifentanil;general anesthetic
14 Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-Blinded Randomized Controlled Trial Completed NCT01591746 Phase 3 Botulinum Toxin Type A;Placebo
15 A Randomized Controlled Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3® for the Treatment of Pain After Breast Surgery. Completed NCT00299039 Phase 3 acetaminophen plus codeine;acetaminophen plus ibuprofen
16 BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer Completed NCT00039780 Phase 3 BNP7787;Placebo
17 Electronic Patient Reported Outcome Measures (ePROMs) in Patients With Breast Disease: An Open-label, Randomized Controlled Trial on Patient Reported Experience Measures (PREMs) and Effectivity (PREMs_PROMs) Completed NCT04718324 Phase 3
18 Efficacy and Safety of Nutritional Supplement ONCOXIN in Patients With Breast Fibrocystic Disease Completed NCT00967681 Phase 3
19 BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation Recruiting NCT04711109 Phase 3 Denosumab;Placebo
20 A Randomized, Controlled, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Breast Cancer and Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Advanced Breast With Liver Metastases Recruiting NCT03500380 Phase 2, Phase 3 RC48-ADC;Lapatinib;Capecitabine
21 Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System Unknown status NCT02511301 Phase 1, Phase 2
22 A Randomized Pivotal Clinical Trial In Breast Cancer Patients Of Pre-Operative Focal Microwave Thermotherapy Treatment For Early-Stage Breast Disease In Intact Breast Unknown status NCT00036998 Phase 2
23 A Multicenter, Open-label, Parallel, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. (Conc. for Fluorescence) Localization in Patients With Nonpalpable Breast Lesions Completed NCT03743259 Phase 2 LuminoMark inj. 0.1mL;LuminoMark inj. 0.2mL;Charcotrace Inj.
24 A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer Completed NCT00050427 Phase 2 ET743
25 Guaraná ("Paullinia Cupana") for Chemotherapy Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study Completed NCT01043913 Phase 2 Guarana extract
26 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation of the Use of Topically Administered Danazol Versus Placebo in Subjects With Pain Associated With Fibrocystic Breast Disease Completed NCT00744276 Phase 2 danazol;Placebo
27 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Completed NCT01849250 Phase 2 Docosahexaenoic Acid
28 Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer Completed NCT01472146 Phase 2 Zo-Nantax
29 A Single-arm, Multi-center Phase II Clinical Study of Pyrotinib Combined With Vinorelbine in the Treatment of HER2-positive and Treated Metastatic Breast Cancer Recruiting NCT04605575 Phase 2 Pyrotinib 320mg + Vinorelbine;Pyrotinib 400mg + Vinorelbine;Pyrotinib plus Vinorelbine
30 A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative Cancers Recruiting NCT03709446 Phase 1, Phase 2 Leflunomide
31 An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer Recruiting NCT05386108 Phase 1, Phase 2 Abemaciclib;Elacestrant
32 TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
33 Targeted Prevention of Postpartum-Related Breast Cancer Recruiting NCT05557877 Phase 2 Low-Dose Aspirin
34 Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*) Recruiting NCT03979508 Phase 2 Abemaciclib
35 A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer Active, not recruiting NCT03304080 Phase 1, Phase 2 Anastrozole;Palbociclib;Trastuzumab;Pertuzumab
36 Pyrotinib Maleate Combined With Trastuzumab Plus Aromatase Inhibitor in the First-line Treatment of Advanced HER2-positive/HR-positive Breast Cancer Phase II Study Not yet recruiting NCT04088110 Phase 2 Pyrotinib;Trastuzumab;Aromatase Inhibitors
37 A Randomized, Open-label Study of First Line Pyrotinib, Trastuzumab With an Aromatase Inhibitors, in the Treatment of HER2 Positive and HR Positive Metastatic or Inoperable Locally Advanced Breast Cancer Not yet recruiting NCT03910712 Phase 2 Pyrotinib;Trastuzumab;Aromatase inhibitor
38 GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer Terminated NCT01499160 Phase 2 letrozole;lapatinib;everolimus
39 A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Completed NCT02897778 Phase 1 Entinostat;Placebo
40 A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460) Completed NCT02909452 Phase 1 Entinostat;Pembrolizumab
41 Phase I Study of a Recombinant Fowl Pox Vaccine rF-CEA (6D)/TRICOM Alone or With GM-CSF in Patients With Advanced CEA Expressing Adenocarinomas Completed NCT00028496 Phase 1
42 Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab Plus Docetaxel and Carboplatin in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer: a Single-arm, Ahead, Open-label Study Unknown status NCT03756064 Pyrotinib;Trastuzumab;Docetaxel;Carboplatin;Placebo Oral Tablet
43 Prospective, Multi-centre, Observational Trial Evaluating Outcomes of Immediate Breast Reconstruction Using an Implant and Acellular Dermal Matrix (SurgiMend) or Autologous Tissue Unknown status NCT02557906
44 A Randomized Study Evaluating the Safety and Effects of the Combination of Palbociclib With Epirubicin and Cyclophosphamide Followed by Paclitaxel as Neoadjuvant Therapy in Triple Negative Breast Cancer Unknown status NCT03756090 Palbociclib;Placebo oral capsule;Epirubicin;Cyclophosphamide;Paclitaxel
45 A Randomized Controlled Comparative Study of Ultrasound-guided Paravertebral Blocks as Part of a Multimodal Regimen for Ambulatory Breast Cancer Surgery Unknown status NCT01654432
46 Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer Unknown status NCT01140763
47 Clinical Application of Breast Blood-oxygen Functional Imaging Technology Unknown status NCT01678170
48 Expedited Discharge of Patients Undergoing Pedicled TRAM Flap Breast Reconstruction Procedure in Ambulatory Surgical Facility: Quality of Recovery Outcomes Unknown status NCT01438268
49 Development of an Artificial Intelligence Precise Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics Unknown status NCT04535466
50 Risk Factors for Benign Breast Disease in Young Adult Women. Case-control Study Unknown status NCT04127422

Search NIH Clinical Center for Breast Disease

Cochrane evidence based reviews: breast diseases

Sources

Genetic Tests for Breast Disease

About this section
Sources

Anatomical Context for Breast Disease

About this section

Organs/tissues related to Breast Disease:

FMA: Breast
MalaCards : Breast, Lymph Node, Skin, Ovary, Liver, Thyroid, Brain
Sources

Publications for Breast Disease

About this section

Articles related to Breast Disease:

(show top 50) (show all 5082)
# Title Authors PMID Year
1
Gut dysbiosis induces the development of mastitis through a reduction in host anti-inflammatory enzyme activity by endotoxemia. 41
36451232 2022
2
The Effectiveness of Herbal Medicines on Cyclic Mastalgia: A Systematic Review on Meta-analysis. 41
36446563 2022
3
Abnormally large malignant breast tumor with breast abscess: a rare clinical image. 41
36451986 2022
4
Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression. 53 62
19308726 2010
5
Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. 53 62
19551864 2010
6
Cells with minimal expression of the JAK/STAT pathway related proteins STAT5a and the prolactin receptor: evidence of an alternate prolactin receptor isoform in breast disease. 53 62
20214633 2010
7
Nipple aspirate fluid collection, related factors and relationship between carcinoembryonic antigen in nipple aspirate fluid and breast diseases in women in Harbin, PRC. 53 62
19273481 2009
8
Estrogen alpha and progesterone receptor expression in the normal mammary epithelium in relation to breast cancer risk. 53 62
18798271 2009
9
Caffeine consumption and the risk of breast cancer in a large prospective cohort of women. 53 62
18852405 2008
10
[mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR]. 53 62
19087676 2008
11
The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. 53 62
17851763 2008
12
Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. 53 62
18379196 2008
13
A comparison of plasma versus histologic indices of angiogenic markers in breast cancer. 53 62
18091379 2007
14
Importance of novel sequence alterations in the FHIT gene on formation of breast cancer. 53 62
18338496 2007
15
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]. 53 62
17557253 2007
16
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. 53 62
17417639 2007
17
Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. 53 62
17431282 2007
18
The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions. 53 62
17164758 2007
19
IGFBP3 mRNA expression in benign and malignant breast tumors. 53 62
17210081 2007
20
[Role of immunocytochemistry in fine needle aspiration cytology diagnosis of mammary lesions of breast]. 53 62
17374259 2006
21
Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. 53 62
16808847 2006
22
Hormones and progeny of breast tumor cells. 53 62
16698656 2006
23
Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. 53 62
16327431 2005
24
[Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer]. 53 62
15946491 2005
25
Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast. 53 62
15508191 2004
26
Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. 53 62
15217931 2004
27
p65 and c-erbB2 genes expression in breast tumors: comparison with some histological typing, grading and clinical staging. 53 62
12866575 2003
28
Clustering of variations and haplotype analysis in the highly variable region of exon 11 of BRCA1 in Chinese women with sporadic breast cancer. 53 62
12402341 2002
29
Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. 53 62
11839578 2002
30
Behaviour of estrogen receptor, histological correlation, and clinical outcome in patients with benign breast disorders. 53 62
12699101 2002
31
Breast cancer risk factors and HER2 over-expression in tumors. 53 62
12132871 2001
32
Association between estradiol, estrogen receptors, total lipids, triglycerides, and cholesterol in patients with benign and malignant breast tumors. 53 62
11282289 2000
33
Serum c-erbB-2 protein in breast cancer patients. 53 62
10998842 2000
34
Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. 53 62
10836299 2000
35
Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype. 53 62
10753193 2000
36
RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters. 53 62
10845277 2000
37
Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. 53 62
10720070 2000
38
Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients. 53 62
10845280 2000
39
HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. 53 62
10637239 2000
40
Angiogenic growth factors in preinvasive breast disease. 53 62
10537355 1999
41
The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol. 53 62
10548314 1999
42
Receiver-operating characteristic (ROC) curve analysis of cathepsin D and pS2 in breast disease; results from a prospective study. 53 62
10629636 1999
43
Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast disease. 53 62
10442920 1999
44
HER-2/neu (c-erb-B2) gene and protein in breast cancer. 53 62
10396301 1999
45
Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. 53 62
10363992 1999
46
Environmental exposure to hexachlorobenzene (HCB) and risk of female breast cancer in Connecticut. 53 62
10350435 1999
47
[Relationship of estrogen and progesterone receptors to the menstrual cycle and menopausal status at the time of breast surgery]. 53 62
10486879 1999
48
Transcriptional activation of functional endogenous estrogen receptor gene expression in MCF10AT cells: a model for early breast cancer. 53 62
9772278 1998
49
Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. 53 62
9760013 1998
50
c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. 53 62
9879773 1998
Sources

Variations for Breast Disease

About this section
Sources

Expression for Breast Disease

About this section
Search GEO for disease gene expression data for Breast Disease.
Sources

Pathways for Breast Disease

About this section

Pathways related to Breast Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.78 VEGFA TP53 TNF RHOC IGF1 ESR2
2
GPCR Pathway 64
Show member pathways
 13.69 VEGFA TP53 RHOC IGF1 ESR2 ESR1
3
TGF-Beta Pathway 64
Show member pathways
 13.54 VEGFA TP53 TNF PRLR IGF1 ERBB2
4
Prolactin Signaling 64
Show member pathways
 13.41 BCL2 EGF ERBB2 IGF1 PRLR RHOC
5
Akt Signaling 64
Show member pathways
 13.4 TP53 TNF RHOC IGF1 ERBB2 EGF
6
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.28 VEGFA TNF IGF1 ESR2 ESR1 ERBB2
7
Signal Transduction 66
13.21 VEGFA TP53 TNF TFF1 RHOC PGR
8
PI3K-Akt signaling pathway 74
Show member pathways
 12.95 VEGFA TP53 PRLR IGF1 EGF BCL2
9
ESR-mediated signaling 66
Show member pathways
 12.91 TFF1 PGR ESR2 ESR1 EGF CTSD
10
TNFR1 Pathway 64
Show member pathways
 12.87 VEGFA TP53 TNF IGF1 EGF CTSD
11
Signaling by Receptor Tyrosine Kinases 66
12.76 CTSD EGF ERBB2 ESR1 IGF1 PGR
12
Malignant pleural mesothelioma 74
12.7 VEGFA TP53 IGF1 EGF BCL2
13
Endometrial cancer 74
Show member pathways
 12.64 VEGFA TP53 IGF1 ERBB2 EGF BCL2
14
Chks in Checkpoint Regulation 64
Show member pathways
 12.61 BCL2 ESR1 ESR2 IGF1 TP53
15
Development EGFR signaling pathway 22
Show member pathways
 12.49 TP53 RHOC ERBB2 EGF
16
Hepatocyte growth factor receptor signaling 74
Show member pathways
 12.45 TP53 ESR1 ERBB2 BCL2
17
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.41 ESR2 ESR1 EGF BCL2
18
Breast cancer pathway 74
Show member pathways
 12.23 TP53 PGR IGF1 ESR2 ESR1 ERBB2
19
Focal adhesion 74
12.22 VEGFA IGF1 ERBB2 EGF BCL2
20
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.21 TFF1 IGF1 ESR2 ESR1 ERBB2 EGF
21
Colorectal Cancer Metastasis 64
12.19 VEGFA TP53 TNF EGF
22
Integrated breast cancer pathway 74
12.14 BCL2 ESR1 TP53 VEGFA
23
MicroRNAs in cardiomyocyte hypertrophy 74
Show member pathways
 12.12 TNF MIR199A1 IGF1 EGF
24
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 12.12 KLK3 IGF1 ERBB2 EGF
25
Direct p53 effectors 61
12.03 TP53 IGFBP3 CTSD BCL2
26
Signaling by ERBB4 66
Show member pathways
 12 PRLR PGR ESR1 ERBB2 EGF
27
Interleukin-4 and Interleukin-13 signaling 66
11.93 VEGFA TP53 TNF BCL2
28
Senescence and autophagy in cancer 74
11.91 TP53 IGFBP3 IGF1 BCL2
29
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 66
Show member pathways
 11.84 VEGFA ESR1 ERBB2
30
Neural Stem Cells and Lineage-specific Markers 65
11.78 VEGFA IGF1 EGF
31
16p11.2 proximal deletion syndrome 74
11.75 TP53 IGFBP3 ESR1
32
Head and neck squamous cell carcinoma 74
11.74 ERBB2 TP53 VEGFA
33
Transcription Ligand-dependent activation of the ESR1/SP pathway 22
Show member pathways
 11.72 VEGFA PRLR ESR1
34
Lung fibrosis 74
11.67 TNF IGF1 EGF
35
Burn wound healing 74
11.64 VEGFA TP53 TNF EGF BCL2
36
Pluripotent stem cell differentiation pathway 74
11.54 VEGFA IGF1 EGF
37
Validated nuclear estrogen receptor alpha network 61
11.53 CTSD ESR1 ESR2 PGR TFF1
38
Tamoxifen metabolism 74
Show member pathways
 11.47 CYP1B1 CYP1A1 COMT
39
Photodynamic therapy-induced HIF-1 survival signaling 74
11.39 VEGFA TP53 IGFBP3
40
LKB1 signaling events 61
11.39 TP53 ESR1 CTSD
41
FOXA1 transcription factor network 61
11.38 TFF1 KLK3 ESR1
42
Ovarian infertility 74
11.37 PRLR PGR ESR2
43
Amyotrophic lateral sclerosis (ALS) 74
11.36 TP53 TNF BCL2
44
Bladder cancer 74
11.36 VEGFA TP53 ERBB2 EGF
45
Estrogen metabolism 74
Show member pathways
 11.31 CYP1B1 CYP1A1 COMT
46
Apoptosis and survival_Anti-apoptotic action of nuclear ESR1 and ESR2 22
11.22 ESR2 ESR1 BCL2
47
Aryl hydrocarbon receptor pathway 74
11.21 VEGFA TNF CYP1B1 CYP1A1
48
Cellular roles of Anthrax toxin 61
11.01 TNF PGR ESR1
49
G-protein signaling_Rap2B regulation pathway 22
10.99 BCL2 EGF ERBB2 IGF1 RHOC TNF
50
Estrogen receptor pathway 74
10.8 ESR1 CYP1B1 CYP1A1
Sources

GO Terms for Breast Disease

About this section

Cellular components related to Breast Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor ternary complex GO:0042567 9.26 IGFBP3 IGF1
2 insulin-like growth factor binding protein complex GO:0016942 8.92 IGFBP3 IGF1

Biological processes related to Breast Disease according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.31 EGF ERBB2 IGF1 PGR TNF TP53
2 negative regulation of apoptotic process GO:0043066 10.3 BCL2 ERBB2 IGF1 PRLR TNF TP53
3 negative regulation of cell population proliferation GO:0008285 10.29 BCL2 CYP1B1 IGFBP3 TFF1 TNF TP53
4 positive regulation of apoptotic process GO:0043065 10.26 TP53 TNF IGFBP3 CYP1B1 CTSD BCL2
5 positive regulation of MAP kinase activity GO:0043406 10.15 VEGFA TNF ERBB2 EGF
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.11 VEGFA TP53 IGF1 EGF
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 10.1 EGF IGF1 TNF VEGFA
8 positive regulation of mitotic nuclear division GO:0045840 10.06 TNF IGF1 EGF
9 positive regulation of epithelial cell proliferation GO:0050679 10.05 VEGFA IGF1 ERBB2 EGF
10 positive regulation of protein kinase B signaling GO:0051897 10.03 VEGFA TNF MIR199A1 IGF1 EGF
11 cell population proliferation GO:0008283 10.02 BCL2 CYP1A1 EGF IGF1 TFF1 TP53
12 positive regulation of smooth muscle cell migration GO:0014911 10.01 IGF1 CYP1B1 BCL2
13 negative regulation of gene expression GO:0010629 9.93 ESR1 IGF1 MIR199A1 PGR TNF TP53
14 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.92 VEGFA TP53
15 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.91 TP53 ESR1
16 B cell lineage commitment GO:0002326 9.91 TP53 BCL2
17 negative regulation of mitotic cell cycle GO:0045930 9.88 TP53 TNF BCL2
18 intracellular steroid hormone receptor signaling pathway GO:0030518 9.88 PGR ESR2 ESR1
19 positive regulation of DNA biosynthetic process GO:2000573 9.85 CYP1B1 TNF VEGFA
20 T cell lineage commitment GO:0002360 9.8 TP53 BCL2
21 positive regulation of epithelial tube formation GO:1905278 9.77 VEGFA EGF
22 positive regulation of MAPK cascade GO:0043410 9.7 VEGFA TNF IGFBP3 IGF1 ERBB2 EGF
23 response to organic cyclic compound GO:0014070 9.65 TNF ESR2 CYP1B1 CYP1A1 BCL2
24 negative regulation of miRNA maturation GO:1903799 9.62 TP53 TNF ESR1
25 mammary gland alveolus development GO:0060749 9.23 VEGFA PRLR ESR1 EGF

Molecular functions related to Breast Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 9.63 PGR ESR2 ESR1
2 estrogen response element binding GO:0034056 9.56 ESR2 ESR1
3 nuclear estrogen receptor activity GO:0030284 9.26 ESR2 ESR1
4 nuclear steroid receptor activity GO:0003707 9.02 PGR ESR2 ESR1
Sources

Sources for Breast Disease

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....